1. Mutational signatures of synchronous and metachronous brain metastases from lung adenocarcinoma
- Author
-
Jianing Chen, Hainan Yang, Chao Zhao, Tao Lin, Da Liu, Weiping Hong, Changguo Shan, Cheng Zhou, Ling Bao, Caicun Zhou, Linbo Cai, Chunxia Su, Zhaoming Zhou, and Lei Wen
- Subjects
Lung adenocarcinoma ,Brain metastasis ,Cerebrospinal fluid ,Diseases of the blood and blood-forming organs ,RC633-647.5 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Brain metastasis (BM) is an important cause of mortality for cancer patients. Many patients were diagnosed with brain metastases at their first visit who have not received any treatment while a subset of patients did not have distant metastases at the first visit and brain metastases were detected during the course of systemic therapies. The difference in their genomic characterization is unclear. 96 lung adenocarcinoma patients were enrolled in our study. 53 patients (55%) had synchronous metastatic brain tumors. 43 (45%) patients had metachronous brain metastases. We performed 168 panel-targeted gene sequencing cerebrospinal fluid (CSF) and plasma samples from patients to identify genomic features of synchronous brain metastases (SBM) and metachronous brain metastases (MBM). In conclusion, CSF liquid biopsies have a priority in detecting gene alteration. A comprehensive comparison of molecular profiling between SBM and MBM revealed the most frequently altered genes in both groups were EGFR and TP53, but with different exon point mutations. RTK-RAS and TP53 pathways were the most affected pathways.
- Published
- 2023
- Full Text
- View/download PDF